Moreover, we observed that the proportion of KRAS mutated patients increased with higher disease stage, a finding supported by Eklöf et al. [30], but not uniformly seen in other cohorts [31,32].Today KRAS mutation status is routinely analysed because of its predictive nature in patients receiving therapeutic antibodies against EGFR, with treatment restricted to patients with KRAS wild type tumours [33,34]. The gene discussed is KRAS; the disease is neoplasm.